The Chronic Kidney Disease (CKD) Drugs Market is being driven by Rising prevalence of CKD globally
The Chronic Kidney Disease (CKD) Drugs Market is expected to grow at a CAGR of 4.77% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 3.81 billion. Pharmaceutical firms are making noteworthy advancements in the research and development of innovative drugs for the treatment of Chronic Kidney Disease (CKD). Regulatory agencies globally are emphasizing the significance of addressing the unmet medical requirements in CKD treatment, leading to an uptick in drug approvals. For instance, in January 2023, Boehringer Ingelheim and Eli Lilly and Company submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Jardiance (empagliflozin) tablets. These tablets are being explored as a potential therapy to decrease the risk of kidney disease progression and cardiovascular disease-related mortality in CKD adults. This approval represents a significant stride in the pharmaceutical industry's ongoing efforts to enhance treatment options for CKD patients.
Get more information on Chronic Kidney Disease (CKD) Drugs Market by requesting a sample report
Which Factors Are Causing a Surge in Market Growth?
The market is segmented based on Drug Class (Erythropoietin stimulating agents, Calcium channel blockers, Phosphate binders, ACE inhibitors, Others) Route Of Administration (Oral, Subcutaneous, Intravenous) Geography (North America, Europe, Asia, Rest of World (ROW)).
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
Key Features in Chronic Kidney Disease (CKD) Drugs Market Research Report
Find out which segment is leading the market by accessing the free PDF report
The Chronic Kidney Disease (CKD) market encompasses various pharmaceutical products, including Calcium acetate and Calcium carbonate, SGLT-2 inhibitors, Calcium Channel Blockers, Beta blockers, Diuretics, and others, used to manage symptoms of kidney failure, hypertension, and diabetes-related complications like Trouble Concentrating and Poor Appetite. ACE Inhibitors, Angiotensin Receptor Blockers, and B-Blockers are also commonly prescribed. Drug approvals continue to expand, driven by the rising prevalence of diabetes, comorbidities, aging populations, and medical technology advancements, such as biologics and renal function enhancement. CKD patients often experience acute exacerbations, requiring additional treatments. Genetic predispositions and Diabetes-related nephropathy further fuel market growth.
The Chronic Kidney Disease (CKD) drugs market is a significant segment of the global pharmaceuticals industry, which encompasses companies and products involved in research and development (R&D) or manufacturing of various drug classes, including Calcium acetate, Calcium carbonate, SGLT-2 inhibitors, and others. The global pharmaceuticals market, a constituent of the wider healthcare sector, was valued at approximately USDX billion in 2023. This market growth is attributed to several factors, including the increasing elderly population, with the number of individuals aged 60 and above projected to rise substantially. Additionally, genetic predispositions, hypertension, and Type 2 diabetes are key drivers for the CKD drugs market. Specifically, conditions such as kidney failure, hypertension, and diabetes necessitate the use of drugs like Calcium acetate, Calcium carbonate, Beta blockers, Diuretics, and SGLT-2 inhibitors. These medications are essential in managing symptoms, preventing complications, and slowing disease progression. The pharmaceuticals market expansion is further fueled by advancements in R&D, regulatory approvals, and increasing healthcare expenditures.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
